V
Vaxdyn
Developing vaccines to prevent antibiotic-resistant infections
About Vaxdyn
Vaxdyn is a biotechnology company dedicated to developing vaccines that target multi-drug resistant bacteria, addressing a critical global health crisis. The company focuses on creating inactivated, endotoxin-free whole cell vaccines that display multiple conserved antigens from pathogens like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. These vaccines aim to establish protective immunity against some of the most dangerous antibiotic-resistant bacteria. Vaxdyn serves healthcare providers and patients in urgent need of new solutions to combat antibiotic-resistant infections. Operating in the biotech and pharmaceutical markets, Vaxdyn's business model revolves around extensive research and development, clinical trials, and eventual commercialization of their vaccine candidates. The company generates revenue through funding from international collaborations, grants, and future sales of their patented vaccine products.
Source: Dealroom company dataAt a glance
- Founded
- 2011
- Headquarters
- Dos Hermanas, Spain
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
CARB-X
Mind the Gap
European Innovation Council
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vaxdyn on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vaxdyn on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.